Article Text

Download PDFPDF
Tumefactive demyelination: an approach to diagnosis and management
  1. Todd A Hardy1,
  2. Jeremy Chataway1,2
  1. 1Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery, London, UK
  2. 2Queen Square MS Centre, Institute of Neurology, University College London, London, UK
  1. Correspondence to Dr Todd Hardy, Box 21, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; thardy{at}


Tumefactive lesions are an uncommon manifestation of demyelinating disease and can pose a diagnostic challenge in patients without a pre-existing diagnosis of multiple sclerosis. Choosing when to biopsy a tumefactive lesion to exclude alternative pathology can be difficult. Other questions include how best to treat an acute attack as well as the optimal timing of therapy to prevent relapse. This article aims to review the available literature for tumefactive demyelination and to propose an approach to diagnosis and management. We argue that disease modifying therapy should be considered for acute tumefactive demyelinating lesions only once criteria of dissemination in time and space are fulfilled and the diagnosis of multiple sclerosis is confirmed.

  • Multiple Sclerosis
  • Neuroimmunology
  • Neuropathology
  • Neuroradiology
  • Tumours

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.